| Document |
Document Title |
|
WO/2019/172175A1 |
[Problem] To provide a novel glycation inhibitor. [Solution] A glycation inhibitor which comprises as an active ingredient an extract of one or more plants selected from the plant group consisting of horseradish (Armoracia lapathifolia),...
|
|
WO/2019/172174A1 |
[Problem] To provide a novel RAGE signaling inhibitor. [Solution] This RAGE signaling inhibitor contains, as an active ingredient, an extract from one or more plants selected from the plant group consisting of Geumjaponicum Thunb., Salvi...
|
|
WO/2019/169113A1 |
The present disclosure provides methods for treating a mammal that has endometriosis using a CHRH1 antagonist composition. In some embodiments, the CHRH1 antagonist is antalarmin or an equivalent.
|
|
WO/2019/161719A1 |
Provided is the use of icarisid II or a pharmaceutically acceptable carrier thereof in erectile dysfunction. The use includes using icarisid II or the pharmaceutically acceptable carrier thereof for, specifically but not limited to, prev...
|
|
WO/2019/163798A1 |
The present invention addresses the problem of providing a novel therapeutic strategy against erectile dysfunction. Disclosed is an erectile dysfunction therapeutic agent that contains a filtrate obtained by filtering a liquid of disrupt...
|
|
WO/2019/162895A1 |
The present invention relates to vaginal topical compositions for use in the treatment of vaginitis and vaginosis, comprising a mixture of biological factors isolated from colostrum and ozonized vegetable oils.
|
|
WO/2019/154899A1 |
The present invention relates to a contraceptive method with reduced cardiovascular effects, such as reduced thromboembolism risk, such as reduced venous thromboembolism (VTE) risk and reduced aortic thromboembolism (ATE) risk. The metho...
|
|
WO/2019/156199A1 |
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune d...
|
|
WO/2019/153051A1 |
Disclosed are compositions useful in the treatment or prevention of endometriosis and pain. Also disclosed are methods for the treatment and/or prevention of endometriosis and pain.
|
|
WO/2019/154161A1 |
The present application relates to a pharmaceutical composition for treating male diseases. The pharmaceutical composition comprises the following component in parts by mass: 10-30 parts of a hot water extract of Maca, 10-30 parts of a h...
|
|
WO/2019/151883A1 |
The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and ...
|
|
WO/2019/149156A1 |
Disclosed are uses of a Pulsatilla saponin compound B4 represented by formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug for treating viral and/or bacterial diseases, such as bovine mastitis, said Pulsatilla sa...
|
|
WO/2019/152745A1 |
The present disclosure relates to proteomic biomarkers of spontaneous preterm birth, proteomic biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides tools for determining whether a pregnant ...
|
|
WO/2019/149158A1 |
The present invention relates to nitrogenous tricyclic compounds and uses thereof in medicine, in particular, the present invention discloses a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a ge...
|
|
WO/2019/145546A1 |
Thus, the present invention provides a method of producing a composition in powder form comprising the following steps (a) to (c): (a) providing highly dispersed silica particles, hydrophobic silica particles, and a cationic surfactant; ...
|
|
WO/2019/146740A1 |
Provided is a novel compound which has D3 receptor antagonism. A compound represented by formula (I) (wherein: ring A represents a non-aromatic heterocycle, etc. substituted by an optionally substituted aromatic heterocyclic group, etc.;...
|
|
WO/2019/130637A1 |
O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyr
osine or a pharmacologically acceptable salt thereof presents a high therapeutic effect against biliary cancer, colon cancer, esophageal cancer, breast cancer, and pancreatic c...
|
|
WO/2019/129310A1 |
Disclosed are a deuterated elagolix derivative, a pharmaceutical composition, and uses thereof. The structure of the deuterated elagolix derivative of the present invention is as shown in formula (X). The deuterated elagolix derivative a...
|
|
WO/2019/124366A1 |
The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(1-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benz
yl] amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt the...
|
|
WO/2019/119273A1 |
Disclosed in the present invention are a GRP1 antagonistic polypeptide and a derivative and an application thereof, the polypeptide sequences being shown in SEQ ID NO. 1-5. The present antagonistic polypeptide binds with GPR1 in vitro, p...
|
|
WO/2019/122783A1 |
The invention relates to food supplements for use in the field of menses, in particular painful and abundant menses. The invention relates to a composition based on potentilla and iron.
|
|
WO/2019/122245A1 |
A method of preparing a mucoadhesive film containing vardenafil or a pharmaceutically acceptable salt of vardenafil, by admixing, in an aqueous liquid carrier, vardenafil or a pharmaceutically acceptable salt of vardenafil, a C3-C12 poly...
|
|
WO/2019/119272A1 |
Disclosed in the present application are a GPR1 antagonistic polypeptide, a derivative thereof and use thereof, and the present application specifically relates to sequences as shown in SEQ ID NOs: 1-8 and derivatives thereof. The deriva...
|
|
WO/2019/117212A1 |
The present invention addresses the problem of providing: a composition for preventing the adsorption of a bacterium belonging to the genus Fusobacterium to a mucosal cell; and a pharmaceutical composition and a food or beverage composit...
|
|
WO/2019/114541A1 |
The present invention relates to the field of medicine, and particularly relates to multiple crystal forms of the compounds of formula (I), a preparation method therefor, pharmaceutical preparations and pharmaceutical compositions contai...
|
|
WO/2019/114123A1 |
Provided in the present invention is a GnRH polypeptide antigen and a preparation method therefor. Further provided is a method for using the GnRH polypeptide antigen to prepare castration vaccines for animals.
|
|
WO/2019/118571A1 |
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediat...
|
|
WO/2019/114543A1 |
The present application relates to the field of medicine, and in particular, to a crystal form of a compound as represented by formula (I), a method for preparing the crystal form, a pharmaceutical composition comprising the crystal form...
|
|
WO/2019/110097A1 |
The invention relates to a composition for the treatment of male infertility. The invention is characterized by a composition comprising L-carnitine and/or acetyl-L-carnitine or prodrugs thereof for the treatment of infertility in men wi...
|
|
WO/2019/107532A1 |
The present invention provides an aptamer that binds to chymase and includes a consensus sequence that is represented by UAACR1N1R2GGGG (provided that the uracil may be thymine). (In the formula, R1 and R2 are arbitrary single bases, and...
|
|
WO/2019/104587A1 |
A pharmaceutical composition and use thereof. The pharmaceutical composition comprises zedoary turmeric oil and borneol. The zedoary turmeric oil comprises oxysophocarpine (germacrone), curdione, furanodiene, curcumol, elemene and curzer...
|
|
WO/2019/100973A1 |
Provided are a glutamate polypeptide-estrogen/anti-estrogen conjugate, synthesis method therefor, composition thereof, and reagent kit. The conjugate comprises a polypeptide and an estrogen or anti-estrogen; the estrogen or anti-estrogen...
|
|
WO/2019/101368A1 |
The present invention relates to methods for increasing embryo implantation rate in an uterus, for preventing embryo implantation failure in a female subject suffering PCOS and for improving pregnancy rate comprising administering a comp...
|
|
WO/2019/103108A1 |
The purpose of the present invention is to prepare a powder preparation for nasal administration that includes, as an active ingredient, a particulate steroid hormone having an average particle size of 50–300μm. The powder preparation...
|
|
WO/2019/096857A1 |
The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresp...
|
|
WO/2019/098241A1 |
Provided is a new pharmaceutical composition which is for mastitis and which is safe and has excellent handling properties and economic efficiency. This pharmaceutical composition for mastitis includes an ozone-dissolved glycerin and is ...
|
|
WO/2019/093909A1 |
The present invention relates to compositions, methods and uses involving an allene oxide synthase in the restoration or improvement of sperm viability, particularly for use in assisted reproductive procedures for humans and in the breed...
|
|
WO/2019/092579A1 |
The present invention relates to the use of Luteolin 2- (3, 4- dihydroxyphenyl) -, 5, 7dihydroxy-4- chromenone in a method for the treatment of endometriosis and symptoms thereof. The present invention further relates to compositions com...
|
|
WO/2019/088010A1 |
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a ...
|
|
WO/2019/086826A1 |
A dietary composition including saw palmetto and coconut oil in a proportion whereby the daily dose provides a controlled amount of fatty acids, having a minimum of 37.5mg lauric acid and 16.44mg myristic acid.
|
|
WO/2019/079869A1 |
The present invention relates to the field of subdermal hormone implants and more specifically to a reservoir of silicone and elastomer with silver nanoparticles. More specifically, the invention relates to an implant with a reservoir co...
|
|
WO/2019/080682A1 |
The present invention relates to the field of pharmaceutical synthesis, and relates to a method for the synthesis of 1,7-di-(4-hydroxyphenyl)-heptane-1,4-dien-3-one. A method for synthesizing 1,7-di-(4-hydroxyphenyl)-heptane-1,4-dien-3-o...
|
|
WO/2019/080811A1 |
The present invention relates to a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of a preparation comprising...
|
|
WO/2019/084546A1 |
Methods and compositions for stimulating ovarian function in a patient suffering from premature ovarian failure and for decreasing recurrent spontaneous abortion are disclosed.
|
|
WO/2019/081343A1 |
The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combin...
|
|
WO/2019/075893A1 |
Provided is a placental chondroitin sulphate A-containing contraceptive immunogenic composition, the immunogenic composition also containing an immunopotentiator. Also provided is a use of the immunogenic composition in the preparation o...
|
|
WO/2019/077407A1 |
In one embodiment, the present invention is directed to a composition comprising an aqueous or ethanolic extract of at least one herb selected from the group consisting of Aloe barbadensis (蔍薈:F3), Rheum palmatum L. (大黄:Β6) Step...
|
|
WO/2019/076942A1 |
The invention relates to a pharmaceutical composition comprising cis-(E)-4-(3-fluorophenyl)- 2',3',4',9'-tetrahydro-N,N-dimethyl-2'-(1-oxo-3-phenyl-2-pro
penyl)-spiro[cyclohexane-1,1'[1H]- pyrido[3,4-b]indol]-4-amine. The pharmaceutical ...
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2019/071902A1 |
Provided is a use of miR-21 in the prepartion of therapeutic drugs or diagnostic reagents for intrauterine adhesion and/or thin endometrium.
|
